SCHEMBL4049757

SCHEMBL4049757

CC1(C)CCN(S(=O)(=O)c2ccc(F)cc2)c2cc(C(=O)N3CCOCC3)ccc2S1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MAPK1 P28482 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
KMT2A Q03164 2/20 0.44
TP53 P04637 1/20 0.44
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44
PKM P14618 2/20 0.43
HSD11B1 P28845 1/20 0.42
POLB P06746 1/20 0.41
LMNA P02545 1/20 0.41
EPHX2 P34913 1/20 0.41
NR1I2 O75469 1/20 0.41
RORC P51449 1/20 0.41
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2000823 0.92 CNR1 (0.48) CYP2C9CYP2C19L3MBTL1SMN1; SMN2KMT2A
SCHEMBL2000042 0.91 TSHR (0.47) ALDH1A1CYP2C9CYP2C19MAPK1L3MBTL1
SCHEMBL1999477 0.85 CNR1 (0.51) SMN1; SMN2KMT2ATP53CNR1CNR2
SCHEMBL1997717 0.84 CNR1 (0.61) ALDH1A1CYP3A4CYP2C9CYP2C19MAPK1
SCHEMBL1996818 0.81 CNR1 (0.49) ALDH1A1SMN1; SMN2KMT2ACNR1CNR2
SCHEMBL2003701 0.81 HPGD (0.48) ALDH1A1CYP3A4CYP2C9SMN1; SMN2KMT2A
SCHEMBL1993673 0.78 CNR2 (0.73) ALDH1A1MAPK1L3MBTL1KMT2ACNR1
SCHEMBL13907098 0.76 CPT2 (0.47) CYP2C9KMT2ATP53CNR1CNR2
SCHEMBL2002323 0.76 MCL1 (0.47) CYP3A4CYP2C9CYP2C19SMN1; SMN2KMT2A
SCHEMBL12567617 0.75 CNR1 (0.46) CNR1CNR2NR1I2RORCNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960376-B2 Benzo-fused heterocycles CARA THERAPEUTICS, INC. (US) 2011-06-14 US disclosed
US-7960376-B2 Benzo-fused heterocycles CARA THERAPEUTICS, INC. (US) 2011-06-14 US disclosed
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 US disclosed
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 US disclosed
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 US disclosed
WO-2009035997-A2 BENZO-FUSED HETEROCYCLES CARA THERAPEUTICS, INC. (US) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075973-A1 BENZO-FUSED HETEROCYCLES CNR1, CNR2, TRPV1 ALDH1A1 1422/4885CYP3A4 411/4885CYP2C9 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.